Replies to post #3748 on Aurinia Pharmaceuticals Inc (AUPH)

[moosedogger]

"Embrace it, except it , it's part of the process."

Here is why I'm not embracing it:

Your apparent view and strategy is far too risky- puts me way out of my comfort zone. Let's even say the odds are 100 to one in your favor- it's still too risky for me.

While it's likely that there are some here who have amateur standing in this category, I am a seasoned professional mistake maker- I may even be modest in saying I'm in the world class rankings.

I've already been fooled so many times by this stock I cannot afford to miss the BO, which easily could come before P3 is completed.

You're more of a gambler than I am.

I see the risk of being out of this stock far greater than being in, especially at these low levels.

I think it was Hans Solo who said to CP3O, "Never tell me the odds".

Frequently wrong but never in doubt

cheers

[faxedreceipts]

This guy has more grey matter than most. It might be wise for you to reconsider your position:

https://twitter.com/KSSMDPhD

[cervelo]

thank you for the reassurance.
your wisdom I Embrace it, I except it , it's part of the process of my becoming a wise and astute investor.

[northern vortex]

I reject the premise that share dilution will be inevitable in order to complete the LN Phase 3 study.

Dr. Glickman can partner or sell off the Japanese rights to Voclosporin for LN and/or DES - with an upfront payment as part of the deal; or DES treatment rights for canines to Merck.

As Pencow pointed out (post 3771), there appears to be more than just potential value in the DES asset based on Merck’s participation in the collaborative research project.

Glickman just has to make the deal before the buyer knows AUPH needs the money in order to get the best price.